Assistant Staff
Email: karaaym@ccf.org
Location:
Cleveland Clinic Main Campus
Our laboratory focuses on understanding the early events in breast cancer development. Two main areas of interest are: (1) studying the somatic genomics of breast cancer in individuals with germline BRCA1/2 predisposing mutations and (2) investigating how tumor heterogeneity contributes to triple-negative breast cancer development and treatment response. We employ state-of-the-art single cell approaches to dissect molecular heterogeneity in pre-malignant and malignant lesions of the breast. Our goal is to leverage the knowledge gained from these studies and develop innovative strategies for breast cancer chemoprevention and treatment.
Research Technician
caputoa@ccf.org
Postdoctoral Fellow
vipparp@ccf.org
View publications for Mihriban Karaayvaz, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
With a grant from the American Cancer Society, Dr. Karaayvaz’s team will investigate the molecular connections linking BRCA2 to breast cancer development with the goal of developing innovative strategies for breast cancer risk assessment and prevention.